Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA).
Status: Recruiting
Location: See all (12) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment in the frames of NDP in Poland.
• Patients willing to participate in the study and signed Informed Consent Form (ICF).
• Vaccination against N. meningitidis
Locations
Other Locations
Poland
Research Site
RECRUITING
Bydgoszcz
Research Site
NOT_YET_RECRUITING
Bydgoszcz
Research Site
RECRUITING
Gdansk
Research Site
NOT_YET_RECRUITING
Katowice
Research Site
RECRUITING
Krakow
Research Site
NOT_YET_RECRUITING
Krakow
Research Site
RECRUITING
Lodz
Research Site
RECRUITING
Lublin
Research Site
WITHDRAWN
Poznan
Research Site
RECRUITING
Szczecin
Research Site
RECRUITING
Warsaw
Research Site
RECRUITING
Wroclaw
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2025-05-15
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 50
Treatments
Ravulizumab
Open-lable arm with gMG patients who received ravulizumab treatment in the frames of NDP in Poland.
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca